Detex schreef op 1 juli 2019 14:02:
Bicycle Therapeutics Ltd. shares soared 29% in premarket trade Monday, after the company announced positive results in a trial of a treatment for diabetic macular edema, or DME, a disease that causes damage in the blood vessels of the retina that can harm vision. The company said the Phase 1 trial conducted by its research partner Oxurion NV evaluating the safety of a single injection of THR-149 at three ascending dose levels in 12 subjects met its goals. "These trial results represent additional human clinical data generated using Bicycles, a new therapeutic modality developed using our proprietary technology," said Kevin Lee, chief executive of Bicycle Therapeutics. Shares have fallen 13% in the last month through Friday. The company went public in late May at $14 a share.